Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01608711 · ClinicalTrials.gov registry record · Phase 2
A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002
A Phase 2 study of Pancreatic Cancer and Carcinoma, Pancreatic Ductal, sponsored by Agensys.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 2
- Study locations
NCT01608711: Completed Phase 2 study of Pancreatic Cancer and Carcinoma, Pancreatic Ductal, sponsored by Agensys.
NCT01608711 is a Phase 2 study of Pancreatic Cancer and Carcinoma, Pancreatic Ductal that has completed, run by Agensys. The registered enrollment target is 2 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01608711, a Phase 2 study of Pancreatic Cancer and Carcinoma, Pancreatic Ductal, has completed, sponsored by Agensys.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to continue the safety and immunogenicity of AGS-1C4D4 administered in combination with gemcitabine in subjects previously treated in protocol 2008002.
Primary Outcome
Grade 3 and 4 adverse events, treatment-related adverse events, serious adverse events and adverse events requiring discontinuation of AGS-1C4D4
Conditions Studied
Interventions
- BIOLOGICAL AGS-1C4D4
- BIOLOGICAL gemcitabine
Study Locations (2)
Wisconsin
- Site US116 - Madison
Other
- Site CA00203 - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-08-07 |
| Est. Completion | 2015-11-16 |
| Phase | Phase 2 |
What the finished NCT01608711 record still lists
NCT01608711 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which AGS-1C4D4 is the first listed.
NCT01608711 reports a single indexed study location in Wisconsin, Other.
Frequently Asked Questions
What is clinical trial NCT01608711 about?
NCT01608711 is a clinical study titled "A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002". The purpose of this study is to continue the safety and immunogenicity of AGS-1C4D4 administered in combination with gemcitabine in subjects previously treated in protocol 2008002.
What is the current status of trial NCT01608711?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-08-07. Estimated completion is 2015-11-16.
What conditions does trial NCT01608711 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Carcinoma, Pancreatic Ductal, Pancreatic Disease.
What interventions are being tested in trial NCT01608711?
The interventions under investigation include: AGS-1C4D4 (BIOLOGICAL), gemcitabine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01608711?
This trial is sponsored by Agensys, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01608711 being conducted?
This trial has 2 study locations across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01608711's enrollment target sits among peer trials
2 278th of 278 the lowest of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI